Summary
FY2027/3 marks the first year of the mid-term management plan "BEYOND2028," with strategic investments exceeding JPY 8B in capex—including construction of a new Indonesian factory and MES implementation—ramping up in earnest. The Sewing business benefited from production capacity expansion centered on Bangladesh, with units sold up +22.1% in the prior fiscal year and FX-adjusted operating income (underlying earnings) of JPY 5,469M, reflecting improved earnings quality. In Q1, investor focus will be on production ramp yields and early-stage progress toward the full-year underlying earnings target of JPY 5,300M (+10.1%). The Lamination Film business saw revenue decline -30.9% in the prior year as a hit product cycled through, and whether signs of a recovery from the trough emerge will be a key inflection point for the investment case. Additionally, with rising uncertainty around U.S. trade policy toward Asia, attention is turning to the extent to which the company's multi-site production network delivers a competitive advantage.
Key Points for Next Quarter
| Key Points & Focus | Implications |
|---|---|
Revenue GrowthQ1 revenue progress rate against full-year guidance of JPY 80B | Back-calculating from the prior year's Q1 revenue mix suggests ~JPY 19B as a benchmark. Upside hinges on the operational status of expanded Bangladesh production lines |
Underlying EarningsYoY trajectory of FX-adjusted operating income | Securing a YoY increase in Q1 against the full-year target of JPY 5,300M (+10.1%) is critical to mid-term plan credibility |
Segment MixYoY comparison of Sewing business unit volumes and gross margin | Whether the growth momentum of 63.5M units (+22.1%) in the prior full year is sustained. Confirmation of continued gross margin improvement driven by rising utilization rates |
Lamination Film BusinessLamination Film business revenue and order trends | Contracted to JPY 8,221M (-30.9%) in the prior year. Focus is on whether the YoY revenue decline narrows as inventory adjustment completes and new demand is captured |
FX AssumptionsActual FX rates vs. company assumptions (USD/JPY 151.3, CNY/JPY 21.2) | A stronger yen would lift operating income via lower JPY-translated overseas subsidiary costs, but would create headwinds for recurring profit as FX gains compress |
Capex ProgressConstruction progress of new Indonesian factory and capex execution | Q1 execution rate against the full-year JPY 8B+ investment plan, and the impact of rising depreciation on margins |
Capital EfficiencyROE improvement trend | 8.0% in the prior year (vs. 7.3% the year before). The mid-term plan positions capital efficiency improvement as a core strategy—whether a path to ROE above 10% is demonstrated |
Key Issues from Previous Results (FY2026/3 Full-Year)
FY2026/3 delivered revenue of JPY 74,251M (+5.2%) and underlying FX-adjusted operating income of JPY 4,813M (+13.7%), with volume expansion in the Sewing business driving earnings. However, revenue declines in the Lamination Film business weighed on overall growth, making the earnings divergence between segments starkly apparent. With segment-level disclosure initiated this fiscal year, transparency into each business's earnings structure has improved. FY2027/3, the first year of "BEYOND2028," enters a phase where the company must simultaneously deliver on both "volume expansion" and "quality improvement."
1. Sewing Business Production Scale-Up and Margin Sustainability
- Prior Year: Sewing business revenue JPY 66,029M (+12.5%), FX-adjusted operating income JPY 5,469M (+57.2%)
- This Quarter Checkpoint: Ramp pace of expanded Bangladesh lines, continuation of order trends in workwear and innerwear
- Key Metrics: Q1 YoY growth in units sold, maintenance of Sewing business FX-adjusted OPM (8.3% on an underlying basis in the prior year)
2. Confirmation of a Bottom in the Lamination Film Business
- Prior Year: Sales volume of 13.64M yards (-25.2%), segment profit JPY 554M (-67.9%)
- This Quarter Checkpoint: Whether customer inventory adjustment has concluded, new order trends in Chinese domestic demand and sportswear applications
- Key Metrics: Q1 YoY sales volume in yards, whether segment margin exceeds the prior-year level (6.7%)
3. Capex Monetization Timing and Cash Flow
- Prior Year: Operating CF JPY 6,071M (+122.9% YoY), investing CF -JPY 4,357M, FCF +JPY 1,714M
- This Quarter Checkpoint: Q1 capex execution amount and pace of depreciation increase, status of long-term borrowing
- Key Metrics: Free cash flow, net debt-to-cash flow ratio trajectory (2.5x in prior year)
4. FX Volatility P&L Impact and Stability of Underlying Earnings
- Prior Year: Reported operating income of JPY 2,174M vs. underlying earnings of JPY 4,813M. The JPY 2,638M difference represents FX gains from operating transactions
- This Quarter Checkpoint: FX rate movements during Q1 and the magnitude of operating transaction FX gains/losses
- Key Metrics: Q1 progress rate against the full-year FX-adjusted operating income target of JPY 5,300M
5. First-Year Progress on Mid-Term Plan "BEYOND2028"
- Prior Year: ROE 8.0% (vs. 7.3% the year before), equity ratio 53.1%, dividend JPY 100 (payout ratio 33.5%)
- This Quarter Checkpoint: Initial progress on mid-term plan KPIs (production capacity growth rate, number of MES-deployed sites)
- Key Metrics: Q1 progress rate for revenue and FX-adjusted operating income against full-year guidance, directional improvement in ROE
Timely Disclosure & Industry Trends
- 2026/05/19Earnings Conference Key Remarks - Announced plans to commence construction of a second sewing factory in Indonesia. Matsuoka Corp to Build New Factory in Indonesia, Investing JPY 8B This Fiscal Year
- 2026/05/14Notice Regarding Variance Between Guidance and Actual Results - FY2026/3 full-year recurring profit exceeded guidance by +14.7%, driven by FX gains. Notice Regarding Variance Between Guidance and Actual Results
- 2026/05/14Notice Regarding Dividend (Commemorative Dividend) - JPY 100 per share including a JPY 10 commemorative dividend for the 70th anniversary. Ordinary dividend planned to increase to JPY 115 next fiscal year, signaling a clear shareholder return stance. Notice Regarding Dividend (Commemorative Dividend)
- 2026/05/14First-year capex plan under the mid-term plan disclosed in earnings supplementary materials - Total investment exceeding JPY 8B including ~JPY 3B for the new Indonesian factory, ~JPY 500M for Bangladesh expansion, ~JPY 200M for MES implementation, etc. FY2026/3 Earnings Supplementary Materials
Previous Quarter Results (FY2026/3 Full-Year Actuals)
Matsuoka Corporation is an apparel OEM with proprietary factories across five countries (China, Vietnam, Bangladesh, Myanmar, and Indonesia). Operating under a two-segment structure—Sewing and Lamination Film—the company provides integrated planning, manufacturing, and logistics services to leading domestic and international brands. In FY2026/3, the Sewing business achieved a +22.1% increase in units sold, driven by Bangladesh factory expansion, leading underlying earnings growth. The period is positioned as having completed the foundation-building for the mid-term plan "BEYOND2028" (FY2028 targets: revenue JPY 90B, recurring profit JPY 6B).
| Item | Amount | YoY | vs. Guidance | Notes |
|---|---|---|---|---|
| Revenue | JPY 74,251M | +5.2% | - | Sewing +12.5%, Lamination Film -30.9% |
| Operating Income | JPY 2,174M | +401.3% | - | JPY-translated overseas subsidiary cost inflation weighed on the prior year; eased in this period |
| FX-Adjusted Operating Income | JPY 4,813M | +13.7% | - | Underlying earnings. Sewing business JPY 5,469M (+57.2%) was the key driver |
| Recurring Profit | JPY 5,391M | +28.4% | +14.7% | Includes JPY 3,154M in FX gains |
| Net Income | JPY 3,117M | +19.9% | +3.9% | Recorded impairment losses of JPY 204M and investment securities disposal losses of JPY 62M |
| EPS | JPY 298.12 | +14.9% | - | - |
Full-Year Actuals vs. Guidance: Recurring profit came in +14.7% above guidance (JPY 5,391M vs. guidance of JPY 4,700M)
Company Information
- Company Name: MATSUOKA CORPORATION
- Ticker: 3611
- Listed Exchange: Tokyo Stock Exchange Standard Market
- Fiscal Year-End: March
- Core Business: Apparel OEM (Sewing business: planning and manufacturing of casualwear, innerwear, workwear, etc. Lamination Film business: development and manufacturing of moisture-permeable, waterproof films). Operates proprietary factories across five countries overseas
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.

